Aperture Therapeutics Advances Innovative Antisense Program for ALS
Aperture Therapeutics, based in California, has recently announced a significant breakthrough in treating Amyotrophic Lateral Sclerosis (ALS) with its pioneering MMP9 antisense oligonucleotide (ASO) program, known as APRTX-003. This first-in-class initiative aims to address two fundamental issues associated with ALS: chronic neuroinflammation and neurodegeneration, which are key contributors to motor neuron degenerative diseases.
Understanding the Role of MMP9
Matrix metalloproteinase-9 (MMP9) plays a crucial dual role within the central nervous system. On one hand, it participates in normal synaptic remodeling. But when abnormally activated, it can drive harmful neuroinflammation and neurodegeneration. Recent studies have shown that MMP9, particularly when produced by microglia, can deconstruct the protective extracellular nets that safeguard motor neurons from stress, which exacerbates the pathological conditions associated with ALS.
Research involving human samples and preclinical models reveals that MMP9 levels are significantly elevated in the spinal cord, cerebrospinal fluid, and serum of ALS patients. Additionally, this elevation is also observed in various other age-related neurodegenerative diseases. Significantly, both genetic depletion and pharmacological inhibition of MMP9 have demonstrated a potential to slow down the degeneration of motor neurons, delay the decline in motor function, and prolong survival in these models.
Innovative Antisense Approach
Despite extensive biological evidence linking MMP9 to ALS, previous attempts to create effective drugs targeting this area have generally been hampered by the limitations of small molecules and antibodies. These previous therapies often suffered from poor selectivity and off-target toxicities. However, Martin Jacko, PhD, the founder and CEO of Aperture Therapeutics, emphasizes that their antisense strategy directly targets MMP9 at the RNA level. This innovative approach aims to navigate the historical challenges while effectively modulating a pathway recognized as vital in ALS development.
Leveraging Advanced Platforms
The MMP9 program exemplifies the capabilities of Aperture Therapeutics' unique platform, which utilizes human genetic evidence combined with machine-learning techniques to refine oligonucleotide designs. The company has successfully identified multiple ASOs that efficiently reduce MMP9 mRNA and protein levels, furthermore, diminishing inflammatory markers linked to ALS pathology in human iPSC-derived microglia. In an exciting development, Aperture has created a specialized humanized MMP9 knock-in mouse model to facilitate essential translational pharmacology studies.
Broader Pipeline and Future Directions
This MMP9 program is a vital component of Aperture's extensive pipeline, which focuses on developing genetics-based oligonucleotide therapeutics aimed at addressing microglial dysfunction and neuroinflammation across several neurodegenerative diseases, including ALS, frontotemporal dementia (FTD), and Alzheimer’s disease (AD). In tandem with their CD33 program, the company is committed to creating a comprehensive portfolio of precision RNA medicines that are intended to restore microglial homeostasis and mitigate the progression of neurodegeneration.
About Aperture Therapeutics
Founded in 2022, Aperture Therapeutics is a preclinical biotechnology firm that focuses on developing groundbreaking oligonucleotide therapies guided by insights from human genetic resilience. The company employs a proprietary strategy that integrates multi-omics analyses, machine-learning-assisted ASO and siRNA design, along with humanized in vivo models, to create genetically validated and clinically relevant treatment targets. Aperture Therapeutics benefits from notable funding sources including the National Institute of Neurological Disorders and Stroke (NINDS/NIH) and various venture capital partners.
Frequently Asked Questions
What is the main focus of Aperture Therapeutics?
Aperture Therapeutics is focused on developing next-generation precision medicines for neurodegenerative diseases using innovative oligonucleotide therapies.
What does the MMP9 program aim to treat?
The MMP9 program targets Amyotrophic Lateral Sclerosis (ALS) by addressing chronic neuroinflammation and neurodegeneration.
How does the antisense approach work?
It directly suppresses MMP9 at the RNA level, aiming to modulate pathways critical in ALS and overcome historical drug development challenges.
What other diseases does Aperture target?
Aperture's pipeline also addresses frontotemporal dementia (FTD), Alzheimer’s disease (AD), and related neurodegenerative conditions.
When was Aperture Therapeutics founded?
Aperture Therapeutics was founded in 2022 as a preclinical biotechnology company.
